---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-029926"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:33:43.771246+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics Q4 2023: oncology revenue $107.9M, ZYNRELEF record $5.6M, 2024 guidance reaffirmed

## Summary
- Full-year 2023 oncology care franchise revenue $107.9M exceeded guidance; net product sales up 11% YoY.
- ZYNRELEF Q4 net product sales record $5.6M (up from $3.9M Q4 2022); acute care franchise sales $6.1M.
- Gross margin improved to 71% in Q4 from 58% a year ago; cash and equivalents $80.4M at year-end.
- FDA approved expanded ZYNRELEF label covering ~13M annual procedures; CrossLink partnership adds up to 650 sales reps.
- 2024 guidance: product revenues $138-158M, adjusted EBITDA $(22)-$3M; VAN program PAS submission on track for Q2 2024.

## SEC filing metadata
- accession: 0000950170-24-029926
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017024029926/0000950170-24-029926-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017024029926/hrtx-20240312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-029926
- JSON: https://secwatch.observer/filing/0000950170-24-029926.json
- Plain text: https://secwatch.observer/filing/0000950170-24-029926.txt

## Key facts
- Earnings Releases
  HERON THERAPEUTICS, INC. /DE/ updated its the three and twelve months ended December 31, 2023 guidance (reaffirmed).
  - Period: the three and twelve months ended December 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On March 12, 2024, Heron Therapeutics, Inc. (“Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023 (“Earnings Press Release”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000095017024029926/0000950170-24-029926-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.